AGT and COVID-19: Although angiotensin II is licensed by the Federal Drug Administration to treat sepsis (known as Giapreza, Davenport, Scully, de Graaf, Brown, & Maguire, 2020), it would be inadvisable as a treatment for COVID‐19 given the detrimental action of angiotensin II on the lungs.